Annual report

Period2024-01-01 → 2024-12-31
Filed2025-03-31
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 150
MetricValuePeriodScopeSource row
Revenue¥2.33T2024-01-01 → 2024-12-31Cons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.50T2021-01-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥1.42T2020-01-01 → 2020-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥323.6bn2024-01-01 → 2024-12-31Cons.Operating profit loss IFRS
Operating income¥139.6bn2023-01-01 → 2023-12-31Cons.Operating profit loss IFRS
Profit before tax¥335.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥163.6bn2021-01-01 → 2021-12-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥190.0bn2020-01-01 → 2020-12-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥343.1bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥125.5bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥148.1bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥347.3bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS
Net income¥125.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS
Total assets¥3.74Tat 2024-12-31Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.82Tat 2021-12-31dCons.Total assets IFRS (5-year summary)
Total assets¥2.63Tat 2020-12-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥961.1bnat 2024-12-31Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.78Tat 2024-12-31Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.73Tat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥2.01Tat 2021-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.85Tat 2020-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥426.2bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥356.9bnat 2020-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥354.6bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥228.9bn2021-01-01 → 2021-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥232.8bn2020-01-01 → 2020-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥265.8bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥95.3bn2021-01-01 → 2021-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥99.9bn2020-01-01 → 2020-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥189.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥95.8bn2021-01-01 → 2021-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥104.9bn2020-01-01 → 2020-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥633.762024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥231.322021-01-01 → 2021-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥273.152020-01-01 → 2020-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥246.782022-01-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥231.152021-01-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥272.352020-01-01 → 2020-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥5,089.58at 2024-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,410.8at 2023-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,100.84at 2022-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,707.64at 2021-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,415.54at 2020-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio73.1%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.3%at 2021-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.5%at 2020-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE13.4%2024-01-01 → 2024-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE5.3%2023-01-01 → 2023-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE6.3%2022-01-01 → 2022-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE6.5%2021-01-01 → 2021-12-31dCons.Rate of return on equity IFRS (5-year summary)
ROE8.2%2020-01-01 → 2020-12-31dCons.Rate of return on equity IFRS (5-year summary)
Employees35,338at 2024-12-31Cons.Number of employees
Employees34,388at 2023-12-31Cons.Number of employees
Employees33,482at 2022-12-31dCons.Number of employees
Employees33,226at 2021-12-31dCons.Number of employees
Employees33,151at 2020-12-31dCons.Number of employees
Revenue¥118.0bn2024-01-01 → 2024-12-31StandaloneOperating revenue1
Revenue¥82.4bn2023-01-01 → 2023-12-31StandaloneOperating revenue1
Revenue¥57.0bn2022-01-01 → 2022-12-31dStandaloneOperating revenue1 (5-year summary)
Revenue¥115.0bn2021-01-01 → 2021-12-31dStandaloneOperating revenue1 (5-year summary)
Revenue¥102.7bn2020-01-01 → 2020-12-31dStandaloneOperating revenue1 (5-year summary)
Operating income¥102.9bn2024-01-01 → 2024-12-31StandaloneOperating income
Operating income¥69.0bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income¥105.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income¥70.0bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥46.4bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥104.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥93.5bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥105.0bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax¥70.0bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income¥106.4bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income¥71.0bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥47.4bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income¥106.0bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥94.4bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.38Tat 2024-12-31StandaloneAssets
Total assets¥1.21Tat 2023-12-31StandaloneAssets
Total assets¥1.27Tat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.25Tat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.21Tat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥309.6bnat 2024-12-31StandaloneLiabilities
Total liabilities¥132.5bnat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.07Tat 2024-12-31StandaloneNet assets
Net assets / equity¥1.08Tat 2023-12-31StandaloneNet assets
Net assets / equity¥1.06Tat 2022-12-31dStandaloneNet assets
Net assets / equity¥1.07Tat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.02Tat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥130.4bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥86.4bnat 2023-12-31StandaloneCash and deposits
EPS (basic)¥196.522024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥130.922023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥87.372022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥195.52021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥174.032020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥1202024-01-01 → 2024-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1102023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002022-01-01 → 2022-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1002021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1002020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,997.67at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,989.83at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,959.51at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,970.44at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,875.15at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio77.6%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.6%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio85.6%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE9.9%2024-01-01 → 2024-12-31StandaloneRate of return on equity (5-year summary)
ROE6.6%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE4.4%2022-01-01 → 2022-12-31dStandaloneRate of return on equity (5-year summary)
ROE10.2%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE9.5%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued552,024,717at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued557,835,617at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees183at 2024-12-31StandaloneNumber of employees
Employees151at 2023-12-31StandaloneNumber of employees
Employees147at 2022-12-31dStandaloneNumber of employees
Employees137at 2021-12-31dStandaloneNumber of employees
Employees111at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 61
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥9.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-12-31−¥3.6bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-12-31−¥3.6bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥51.8bn
Consumer Productsreportable segmentcapex2024-01-01 → 2024-12-31¥3.6bn
Consumer Productsreportable segmentemployeesat 2024-12-31604 pure
Consumer Productsreportable segmentrevenue2024-01-01 → 2024-12-31¥33.8bn
Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-12-31¥33.8bn
Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥7m
Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-12-31¥23.0bn
Nutraceuticalsreportable segmentcapex2024-01-01 → 2024-12-31¥54.2bn
Nutraceuticalsreportable segmentemployeesat 2024-12-319166 pure
Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-12-31¥557.0bn
Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-12-31¥557.0bn
Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥37m
Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-12-31¥59.8bn
Otherreportable segmentcapex2024-01-01 → 2024-12-31¥7.7bn
Otherreportable segmentemployeesat 2024-12-312756 pure
Otherreportable segmentrevenue2024-01-01 → 2024-12-31¥113.7bn
Otherreportable segmentrevenue external2024-01-01 → 2024-12-31¥110.1bn
Otherreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥3.6bn
Otherreportable segmentsegment profit2024-01-01 → 2024-12-31¥7.5bn
Pharmaceuticalsreportable segmentcapex2024-01-01 → 2024-12-31¥252.0bn
Pharmaceuticalsreportable segmentemployeesat 2024-12-3121421 pure
Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-12-31¥1.63T
Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-12-31¥1.63T
Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-12-31¥285.1bn
—segment totalcapex2024-01-01 → 2024-12-31¥317.4bn
—segment totalemployeesat 2024-12-3133947 pure
—segment totalrevenue2024-01-01 → 2024-12-31¥2.33T
—segment totalrevenue external2024-01-01 → 2024-12-31¥2.33T
—segment totalrevenue intersegment2024-01-01 → 2024-12-31¥3.6bn
—segment totalsegment profit2024-01-01 → 2024-12-31¥375.4bn
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥12.5bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-12-31−¥3.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-12-31−¥3.3bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥50.7bn
Consumer Productsreportable segmentcapex2023-01-01 → 2023-12-31¥3.8bn
Consumer Productsreportable segmentrevenue2023-01-01 → 2023-12-31¥37.1bn
Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-12-31¥37.1bn
Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥14m
Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-12-31¥12.1bn
Nutraceuticalsreportable segmentcapex2023-01-01 → 2023-12-31¥105.8bn
Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-12-31¥483.5bn
Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-12-31¥483.3bn
Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥138m
Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-12-31¥34.2bn
Otherreportable segmentcapex2023-01-01 → 2023-12-31¥5.4bn
Otherreportable segmentrevenue2023-01-01 → 2023-12-31¥110.2bn
Otherreportable segmentrevenue external2023-01-01 → 2023-12-31¥107.0bn
Otherreportable segmentrevenue intersegment2023-01-01 → 2023-12-31¥3.2bn
Otherreportable segmentsegment profit2023-01-01 → 2023-12-31¥278m
Pharmaceuticalsreportable segmentcapex2023-01-01 → 2023-12-31¥83.6bn
Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-12-31¥1.39T
Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-12-31¥1.39T
Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-12-31¥143.7bn
—segment totalcapex2023-01-01 → 2023-12-31¥198.5bn
—segment totalrevenue2023-01-01 → 2023-12-31¥2.02T
—segment totalrevenue external2023-01-01 → 2023-12-31¥2.02T
—segment totalrevenue intersegment2023-01-01 → 2023-12-31¥3.3bn
—segment totalsegment profit2023-01-01 → 2023-12-31¥190.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 2,346
ItemContextValueUnit
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember1249000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember1072932000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-03-31
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第17期(自 2024年1月1日 至 2024年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)大塚ホールディングス株式会社
Company name in english cover pageFilingDateInstantOtsuka Holdings Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長兼CEO  井上 眞
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都千代田区神田司町二丁目9番地(同所は登記上の所在地であり、実際の業務は下記の最寄りの連絡場所で行っております。)
Telephone number address of registered headquarter cover pageFilingDateInstant03-6717-1410
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)財務会計部課長  小宅 圭子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区港南二丁目16番4号 品川グランドセントラルタワー12階
Telephone number nearest place of contact cover pageFilingDateInstant03-6717-1410
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)財務会計部課長  小宅 圭子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE21183
Fund codeFilingDateInstant-
Security codeFilingDateInstant45780
Filer name in japaneseFilingDateInstant
Original text (Japanese)大塚ホールディングス株式会社
Filer name in englishFilingDateInstantOtsuka Holdings Co., Ltd.
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2024-01-01
Current period end dateFilingDateInstant2024-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2024-12-31
Previous fiscal year start dateFilingDateInstant2023-01-01
Comparative period end dateFilingDateInstant2023-12-31
Previous fiscal year end dateFilingDateInstant2023-12-31
Next fiscal year start dateFilingDateInstant-
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant-
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant-
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Business results of reporting company (text)FilingDateInstantText · Plus
Company history (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Overview of affiliated entities (text)FilingDateInstantText · Plus
Information about employees (text)FilingDateInstantText · Plus
Consolidated subsidiaries metrics of consolidated subsidiariesCurrentYearInstant_Row1Member
Original text (Japanese)大塚製薬㈱

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass